Ontology highlight
ABSTRACT: Background
Shiga toxin-producing E. coli (STEC) infections affect children and adults worldwide, and treatment remain solely supportive. Up to 15-20% of children infected by high-risk STEC (i.e., E. coli that produce Shiga toxin 2) develop hemolytic anemia, thrombocytopenia, and kidney failure (i.e., hemolytic uremic syndrome (HUS)), over half of whom require acute dialysis and 3% die. Although no therapy is widely accepted as being able to prevent the development of HUS and its complications, several observational studies suggest that intravascular volume expansion (hyperhydration) may prevent end organ damage. A randomized trial is needed to confirm or refute this hypothesis.Methods
We will conduct a pragmatic, embedded, cluster-randomized, crossover trial in 26 pediatric
SUBMITTER: Freedman SB
PROVIDER: S-EPMC10224603 | biostudies-literature | 2023 May
REPOSITORIES: biostudies-literature